Sex modifies the Associations of APOE ε4 with Neuropsychiatric Symptom Burden in Both At-Risk and Clinical Cohorts of Alzheimer’s Disease

Manuscript Number: 

22-0586R2

Author(s): 
Christopher R. Bowie, Meryl A. Butters, Nathan Churchill, Andrew S. Dissanayake, Corinne E. Fischer, Alastair Flint, Damien Gallagher, Angela Golas, Nathan Herrmann, Zahinoor Ismail, James L. Kennedy, Sanjeev Kumar, Krista L. Lanctôt, Linda Mah, Anika Maraj, Benoit H. Mulsant, David G. Munoz, Bruce Pollock, Tarek K. Rajji, Tom A. Schweizer, Yu Bin Tan, Michael Tau, Debby W. Tsuang

Disclosures

Christopher R. Bowie

  • Nothing to Disclose

Meryl A. Butters

  • Nothing to Disclose

Nathan Churchill

  • Nothing to Disclose

Andrew S. Dissanayake

  • Nothing to Disclose

Corinne E. Fischer

  • Grants
    • Agency: 
      Hoffman La Rcohe
      Dates: 
      2018-2022
    • Agency: 
      Vielight Inc
      Dates: 
      2019-2022
    • Agency: 
      Cortexyme
      Dates: 
      2019
    • Agency: 
      Novo Nordisk
      Dates: 
      2022

Alastair Flint

  • Nothing to Disclose

Damien Gallagher

  • Nothing to Disclose

Angela Golas

  • Nothing to Disclose

Nathan Herrmann

  • Nothing to Disclose

Zahinoor Ismail

  • Consulting Fees:
    Advisory Boards - Otsuka/Lundbeck Advisory Boards - Acadia, Roche - paid to institution

James L. Kennedy

  • Nothing to Disclose

Sanjeev Kumar

  • Nothing to Disclose

Krista L. Lanctôt

  • Consulting Fees:
    BioXcel Therapeutics, Bright Minds, Cerevel Therapeutics, Eisai Co. Ltd, Exciva, ICG Pharma, Jazz Pharmaceuticals, Kondor Pharma, H Lundbeck A/S, Merck, Novo Nordisk, Praxis Therapeutics, Sumitomo Pharma Co. Ltd
    Equity:
    Highmark Interactive

Linda Mah

  • Nothing to Disclose

Anika Maraj

  • Nothing to Disclose

Benoit H. Mulsant

  • Sponsors:
    Dr. Mulsant receives personal and research funding from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He also receives compensation from the Department of Psychiatry, University of Toronto, Toronto, Ontario.
    Grants
    • Agency: 
      Brain Canada
    • Agency: 
      Canadian Institutes of Health Research
    • Agency: 
      CAMH Foundation
    • Agency: 
      Patient_Centred Outcomes Research Institute
    • Agency: 
      US National Institutes of Health
    • Agency: 
      Capital Solution Design LLC
    • Agency: 
      HAPPYneuron

David G. Munoz

  • Nothing to Disclose

Bruce Pollock

  • Patents/Royalties
    Dr. Pollock holds United States Provisional Patent Nos. 6/490,680, 17/396,030 and Canadian Provisional Patent No. 3,054,093 for a cell-based assay and kits for assessing serum anticholinergic activity.

Tarek K. Rajji

  • Consulting Fees:
    Participated in 2021 and 2022 in an advisory board for Biogen Canada Inc.
    Patents/Royalties
    Holder of the United States Provisional Patent No. 17/396,030 that describes cell-based assays and kits for assessing serum cholinergic receptor activity.

Tom A. Schweizer

  • Nothing to Disclose

Yu Bin Tan

  • Nothing to Disclose

Michael Tau

  • Nothing to Disclose

Debby W. Tsuang

  • Nothing to Disclose